Company Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
The company was founded in 2000 and is headquartered in Tübingen, Germany.
| Country | DE |
| IPO Date | Aug 14, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 999 |
| CEO | Dr. Alexander Zehnder M.B.A., M.D. |
Contact Details
Address: Friedrich-Miescher-Strasse 15 Tübingen, DE | |
| Website | https://www.curevac.com |
Stock Details
| Ticker Symbol | CVAC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001809122 |
| CUSIP Number | N2451R105 |
| ISIN Number | NL0015436031 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexander Zehnder M.B.A., M.D. | Chief Executive Officer, MD & Member of Management Board |
| Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board |
| Dr. Malte Greune Ph.D. | Chief Operating Officer, Member of Management Board & MD |
| Dr. Myriam Mendila M.D. | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board |
| Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior Vice President & Area Head of Oncology |
| Marco Rau L.L.M., Ph.D. | General Counsel |
| Slavica Stevanovic-Heck | Head of Human Resources |
| Thaminda Ramanayake | Chief Business Officer & Member of Executive Board |
| Thorsten Schuller | Head of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 6-K | Filing |
| Nov 12, 2024 | 6-K | Filing |
| Nov 04, 2024 | 6-K | Filing |
| Nov 04, 2024 | 6-K | Filing |
| Sep 13, 2024 | 6-K | Filing |
| Sep 12, 2024 | 6-K | Filing |
| Sep 09, 2024 | 6-K | Filing |
| Aug 15, 2024 | 6-K | Filing |
| Aug 15, 2024 | 6-K | Filing |
| Aug 15, 2024 | 6-K | Filing |